Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Acquired hemophilia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Acquired hemophilia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Acquired hemophilia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Aortopulmonary Septal Defect Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Aortopulmonary Septal Defect Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Aortopulmonary Septal Defect in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Acquired coagulation factor deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Acquired coagulation factor deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Acquired coagulation factor in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Acquired Immunodeficiency Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Acquired Immunodeficiency Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Acquired Immunodeficiency in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Gonadal Dysgenesis, 46,XX Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Gonadal Dysgenesis, 46,XX Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Gonadal Dysgenesis, 46,XX in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Stenosis, Pulmonary Vein Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Stenosis, Pulmonary Vein Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Stenosis, Pulmonary Vein in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Cutis Laxa Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Cutis Laxa Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Cutis Laxa with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
46, XX Disorders of Sex Development Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
46, XX Disorders of Sex Development Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate 46, XX Disorders of Sex in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
3-Methylglutaconic Aciduria Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
3-Methylglutaconic Aciduria Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate 3-Methylglutaconic Aciduria in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Familial Anomalous Origin of Right Pulmonary Artery Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Familial Anomalous Origin of Right Pulmonary Artery Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Familial Anomalous Origin of in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Obesity, Abdominal Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Obesity, Abdominal Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Obesity, Abdominal with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Anemia, Aplastic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Anemia, Aplastic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Anemia, Aplastic with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →